Blood test for melanoma with BRAF V600E mutation
Part of Cancer, Skin clinical trials.
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have confirmed skin (cutaneous) melanoma.
- Your melanoma has the BRAF V600E mutation.
- You are able and eligible to receive either BRAF/MEK targeted pills (BRAFi/MEKi) or immunotherapy that helps your immune system (checkpoint blockade).
- Your life expectancy is at least 8 weeks.
- You can and are willing to sign informed consent and have blood drawn as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new blood test to detect a specific gene change (BRAF V600E) in melanoma that has come back. The test uses a technology called CRISPR to find the mutation in a simple blood draw, which could help guide treatment without needing a tissue biopsy.
This study looks at your melanoma's gene activity and a blood test for tumor DNA to help predict the risk of the cancer coming back. You will need to provide blood and tissue samples, and the goal is to find better ways to personalize treatment for people with thicker, high-risk melanomas.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study looks at whether a simple blood test can track how well immunotherapy is working in people with advanced melanoma. It might help doctors see if the treatment is effective earlier than with scans alone.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
Hear when a new Liquid Biopsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.